J. Goldman & Co’s CorMedix CRMD Stock Holding History

J. Goldman & Co’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-457,320	Closed	-$3.7M	–	507
2024 Q4	$3.7M	Buy	457,320 +314,880	+221%	+$3.14M	0.1%	217
2024 Q3	$1.15M	Buy	+142,440	New	+$771K	0.03%	276

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

J. Goldman & Co's CRMD Position: Q1 2025 in Review

J. Goldman & Co sold out of CorMedix (CRMD) in Q1 2025, closing a stake of 457,320 shares — an estimated $3.7M sold.

J. Goldman & Co first reported a position in CRMD in Q3 2024 and held it in 2 quarters. The position peaked at $3.7M in Q4 2024. 137 funds tracked by Wall St. Rank hold CRMD as of Q1 2025.

J. Goldman & Co reported no remaining CorMedix position as of Q1 2025 after selling out during the quarter.
J. Goldman & Co sold 457,320 CorMedix shares in Q1 2025, an estimated $3.7M.
J. Goldman & Co first reported a position in CorMedix in Q3 2024 and held it in 2 quarters.
J. Goldman & Co's CorMedix position peaked at $3.7M in Q4 2024.
137 funds tracked by Wall St. Rank held CorMedix as of Q1 2025.

Based on J. Goldman & Co's 13F filing for Q1 2025, filed 15 May 2025.